| IVP 0.082 256.52% | OCG 0.0118 4.42% | SOXS 2.28 0.48% | SEGG 0.9267 79.91% | ZSL 2.82 -14.80% | MTEN 0.0353 4.75% | SLV 84.56 7.58% | SAFX 0.1373 -17.74% | NVDA 183.14 -1.44% | INTC 48.72 3.02% | ASST 1.03 6.19% | TZA 6.16 -1.99% | TQQQ 53.83 -3.18% | JTAI 0.4546 13.65% | DVLT 0.7182 -10.33% | SPY 690.36 -0.49% | PSTV 0.2904 -38.23% | BBAI 6.26 2.79% | IBIT 55.44 3.49% | ONDS 13.56 -2.38% | MSTX 5.2 7.22% | PLUG 2.35 3.07% | ROLR 18.89 436.65% | XLE 48.06 2.26% | QQQ 619.55 -1.07% | TSLL 18.07 -3.58% | BAC 52.48 -3.78% | SOXL 55.38 -1.23% | ASBP 0.0587 -26.44% | BMNR 32.68 4.68% | BITO 13.56 3.39% | TSLS 5.19 1.76% | DUST 5.8 -0.68% | AAL 15.14 -1.37% | BITF 2.94 -5.47% | FNGD 5.51 5.15% | DNN 3.49 4.33% | ACHR 8.91 5.19% | CLSK 13.34 6.29% | F 13.835 -1.04% | JDST 2.11 -0.71% | XLF 54.15 -0.15% | CRML 17.925 32.58% | BEEM 1.87 5.65% | ETHA 25.59 5.66% | TSLA 439.2 -1.79% | OPEN 6.64 -1.92% | MARA 11.11 1.46% | PBR 12.66 2.93% | SIDU 3.75 20.58%

HealthEquity, Inc. (NASDAQ: HQY) Maintains Strong Financial Performance

HealthEquity, Inc. (NASDAQ: HQY) is a prominent player in the medical services industry, specializing in health savings accounts (HSAs) and related financial services. The company is known for its strong financial performance and strategic initiatives aimed at enhancing member savings, spending, and investment strategies. HealthEquity competes with other financial service providers in the healthcare sector, striving to maintain its market position through consistent growth and innovation.

On December 4, 2025, Citigroup maintained its "Outperform" rating for HQY, with the stock priced at $98.64. This rating reflects confidence in HealthEquity's ability to deliver strong financial results and maintain its competitive edge. Citizens JMP also raised the price target for HQY from $117 to $122, as highlighted by TheFly, indicating positive expectations for the company's future performance.

HealthEquity's recent Q3 2026 earnings call, as reported by Seeking Alpha, showcased the company's impressive financial results. The company reported earnings of $1.01 per share, surpassing the Zacks Consensus Estimate of $0.90 per share. This represents a 12.22% earnings surprise and a significant increase from the $0.78 per share reported in the same quarter last year. HealthEquity has consistently exceeded consensus EPS estimates in three of the past four quarters.

In terms of revenue, HealthEquity generated $322.16 million for the quarter ending October 2025, exceeding the Zacks Consensus Estimate by 0.69%. This marks a 7% increase from the $300.43 million reported in the same period last year. The company's strong revenue growth is a testament to its ability to capitalize on market opportunities and deliver value to its stakeholders.

HealthEquity's strategic initiatives have also contributed to its financial success. The company returned $93.7 million to shareholders through stock repurchases and implemented a $2.25 billion 5-year Treasury bond hedge to mitigate HSA cash repricing risk. With total HSA assets growing by 15% to $34.4 billion, HealthEquity continues to demonstrate its commitment to enhancing member savings and investment strategies.

Published on: December 4, 2025